Literature DB >> 29734070

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Barbara Mora1, Toni Giorgino2, Paola Guglielmelli3, Elisa Rumi4, Margherita Maffioli1, Alessandro Rambaldi5, Marianna Caramella6, Rami Komrokji7, Jason Gotlib8, Jean Jacques Kiladjian9, Francisco Cervantes10, Timothy Devos11, Francesca Palandri12, Valerio De Stefano13, Marco Ruggeri14, Richard T Silver15, Giulia Benevolo16, Francesco Albano17, Chiara Cavalloni4, Daniela Barraco1, Daniela Pietra4, Tiziano Barbui18, Giada Rotunno3, Alessandro Maria Vannucchi3, Francesco Passamonti19.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29734070     DOI: 10.1016/j.leukres.2018.04.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.

Authors:  Barbara Mora; Paola Guglielmelli; Andrew Kuykendall; Elisa Rumi; Margherita Maffioli; Francesca Palandri; Valerio De Stefano; Marianna Caramella; Silvia Salmoiraghi; Jean-Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Marco Ruggeri; Richard T Silver; Francesco Albano; Giulia Benevolo; David M Ross; Matteo G Della Porta; Timothy Devos; Giada Rotunno; Rami S Komrokji; Ilaria C Casetti; Michele Merli; Marco Brociner; Domenica Caramazza; Giuseppe Auteri; Tiziano Barbui; Daniele Cattaneo; Lorenza Bertù; Luca Arcaini; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Leukemia       Date:  2022-08-30       Impact factor: 12.883

Review 2.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26

3.  Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Authors:  Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

4.  Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.

Authors:  Ik-Chan Song; Sang Hoon Yeon; Myung-Won Lee; Hyewon Ryu; Hyo-Jin Lee; Hwan-Jung Yun; Seon Young Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2022-03-31

Review 5.  Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Authors:  Barbara Mora; Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2022-09-01       Impact factor: 4.213

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.